Abstract
Hepatic veno-occlusive disease (VOD) of the liver is a common complication following high-dose cytotoxic therapy for bone marrow transplantation (BMT). The major pathological changes are seen in centrilobular (zone 3) hepatocytes and adjacent endothelium. Glutathione (GSH) becomes depleted following chemotherapy and experimental evidence suggests reduced levels predispose to centrilobular hepatocyte and endothelial cell injury. Animal studies have shown that glutamine infusions can maintain GSH levels and protect against free radical injury. We have prospectively studied the effect of glutamine supplementation during BMT. Thirty-four patients undergoing BMT were randomised to receive either glycl-L-glutamine (n = 18) or an isonitrogenous mixture of non-essential amino acids (n = 16). Glutamine was shown to significantly preserve protein C (days +4 and +7, P < 0.05) and albumin levels (days 0 and +4, P < 0.02). markers of thrombin and plasmin generation (thrombin-antithrombin, prothrombin fragment f1+2 and plasmin-antiplasmin levels) were not significantly changed between the two groups. these findings suggest that glutamine preserves hepatic function but does not alter thrombin or plasmin generation during bmt. previous studies have shown reductions in protein c, albumin, factor x and factor vii levels post bmt. falling protein c levels have been shown to be predictive of severe vod. these data suggest a role for glutamine in the protection of hepatic function following bmt.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brown, S., Goringe, A., Fegan, C. et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 22, 281–284 (1998). https://doi.org/10.1038/sj.bmt.1701321
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701321